vancomycin has been researched along with Obesity in 59 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (3.39) | 18.7374 |
1990's | 1 (1.69) | 18.2507 |
2000's | 3 (5.08) | 29.6817 |
2010's | 42 (71.19) | 24.3611 |
2020's | 11 (18.64) | 2.80 |
Authors | Studies |
---|---|
Abutaleb, NS; Elsebaei, MM; Hagras, M; Li, D; Mahgoub, AA; Mayhoub, AS; Mohammad, H; Seleem, MN | 1 |
Chan, A; Chua, HC; D'Argenio, DZ; de Souza, H; Mergenhagen, KA; Nguyen, TD; Shah, AP; Smith, NM; Wilkinson, LA | 1 |
Imoto, W; Kakeya, H; Kawaguchi, H; Kuwabara, G; Nakamura, Y; Sakurai, N; Shibata, W; Yamada, K | 1 |
Altindis, E; Blaak, EE; Canfora, EE; Cederquist, C; Dirice, E; Figura, M; Fujisaka, S; Girdhar, K; Goossens, GH; Hu, J; Huang, Q; Kahn, CR; Kulkarni, RN; Orliaguet, L; Raisingani, A; Soto, M; Sundaresh, B | 1 |
Jones, GR; Reuter, SE; Stocker, SL; Wong, S | 1 |
Erstad, BL; Matthias, KR; Nix, DE | 1 |
Bakker, GJ; Bekkering, S; Cani, PD; Dallinga-Thie, GM; de Clercq, NC; Groen, AK; Hartstra, AV; Herrema, H; Kemper, EM; Koopen, AM; Kroon, J; Meessen, ECE; Nieuwdorp, M; Scheithauer, TP; Schnitzler, JG; Soeters, MR; van Raalte, DH; Winkelmeijer, M | 1 |
Crass, RL; Dunn, RD; Hong, J; Krop, LC; Pai, MP | 1 |
Batchelder, N; Frens, J; Lutheran, CF | 1 |
Bannan, A; Diab, J; Pollitt, T | 1 |
Ding, X; He, X; Pan, Y; Wang, F; Wang, W; Yang, X; Yao, X | 1 |
Cusumano, JA; Huttner, A; Klinker, KP; LaPlante, KL; Luther, MK; Roberts, JA | 1 |
Colin, PJ; Eleveld, DJ; Hart, A; Thomson, AH | 1 |
Hartinger, JM; Pilková, A | 1 |
Hartinger, J; Hronová, K; Šíma, M; Slanař, O | 1 |
Brown, ML; Childress, DT; Gaillard, PR; Hutchison, AM; McAtee, AM | 1 |
Baumgartner, S; Blaak, EE; Goossens, GH; Groen, AK; Konings, MCJM; Lütjohann, D; Plat, J; Reijnders, D | 1 |
Belliveau, P; Bylo, M; Durand, C; Howard, B | 1 |
Chin, SJ; Clarke, HD; Moore, GA; Spangehl, MJ; Young, SW; Zhang, M | 1 |
Bullock, K; Clish, CB; Fujisaka, S; Herzog, C; Kahn, CR; Pacheco, JA; Soto, M | 1 |
Chaix, A; Chang, MW; Knight, R; Marotz, CA; Panda, S; Saghatelian, A; Xu, ZZ; Zarrinpar, A | 1 |
Blaak, EE; Goossens, GH; Hermes, GDA; Reijnders, D; Smidt, H; Zoetendal, EG | 1 |
Fresco, P; Gonçalves, J; Hahn, SR; Monteiro, JF | 1 |
Crass, RL; Dunn, R; Hong, J; Krop, LC; Pai, MP | 1 |
Attou, R; De Bels, D; Gallerani, A; Honore, PM; Kugener, L; Redant, S; Spapen, HD | 1 |
Fukui, H; Inoue, Y; Miwa, H; Oshima, T; Ran, Y; Tomita, T; Watari, J; Xu, X | 1 |
Burgess, DS; Hall, RG; Rutter, WC | 1 |
Clarke, SF; Cotter, PD; Murphy, EF; O'Sullivan, O; O'Toole, PW; Ross, RP; Shanahan, F | 1 |
Heble, DE; Hunstad, DA; McPherson, C; Nelson, MP | 1 |
Bolac, C; Brassat, S; Camus, M; Cante, V; Guillet, G; Paquier-Valette, C | 1 |
Ackermans, MT; Blaak, EE; Dallinga-Thie, GM; de Vos, WM; Fuentes, S; Groen, AK; Hoekstra, JB; Holleman, F; Holst, JJ; Jonker, L; Kema, IP; Knaapen, M; Knop, FK; Kootte, RS; Nieuwdorp, M; Out, C; Reijnders, D; Reuling, I; Romijn, JA; Serlie, MJ; Soeters, MR; Stroes, ES; van der Ley, C; van Nood, E; Vrieze, A; Zoetendal, EG | 1 |
Hwang, I; Ka, S; Kim, JB; Kim, YN; Kim, YR; Lee, HY; Park, YJ; Seok, YJ; Seong, JK | 1 |
O'Donnell, EP; Richardson, J; Scheetz, M | 1 |
Denetclaw, TH; Dowling, TC; Moua, M; Steinke, D; Yu, MK | 1 |
Hong, J; Johns, T; Krop, LC; Pai, MP | 1 |
Bradley, JS; Capparelli, EV; Le, J; Nguyen, A; Romanowski, GL; Tran, TM; Wahid, U; Wu, YS | 1 |
Davies, SW; Dietch, ZC; Efird, JT; Guidry, CA; Hennessy, SA; Sawyer, RG; Shah, PM; Willis, RN | 1 |
Caffrey, AR; LaPlante, KL; Morrill, HJ; Noh, E | 1 |
Linder, KE; Nolan, WC | 1 |
Levine, AR; Lin, H; Yeh, DD | 1 |
Blaak, EE; Boekschoten, MV; Dejong, CH; Goossens, GH; Groen, AK; Hermes, GD; Holst, JJ; Kootte, RS; Lenaerts, K; Most, J; Neis, EP; Nieuwdorp, M; Olde Damink, SW; Reijnders, D; Smidt, H; van der Beek, CM; Zoetendal, EG | 1 |
Hanrahan, TP; Lipman, J; Roberts, JA | 1 |
Hong, J; Krop, L; Pai, MP | 1 |
Angelakis, E; Casalta, JP; Habib, G; Raoult, D; Richet, H; Thuny, F | 1 |
Medico, CJ; Walsh, P | 1 |
Edwards, MS; Kim, S; Moffett, BS | 1 |
Boro, MS; Leong, JV; Winter, M | 1 |
Aubron, C; Cheng, AC; Corallo, CE; Dooley, MJ; Nunn, MO; Poole, S | 1 |
Aubron, C; Cheng, AC; Corallo, CE; Dooley, MJ; Nunn, MO | 1 |
Chavez-Bueno, S; Hagemann, TM; Harrison, D; Johnson, PN; Miller, JL; Miller, M | 1 |
Clarke, SF; Cotter, PD; Daly, C; Fouhy, F; Hogan, A; Joyce, A; Marques, TM; Murphy, EF; O'Doherty, RM; O'Sullivan, O; O'Toole, PW; Quigley, EM; Ross, PR; Shanahan, F; Stanton, C | 1 |
Grace, E | 1 |
Alexander, DP; DeRyke, CA; Reynolds, DC; Waite, LH | 1 |
Brøsen, K; Frimodt-Møller, N; Gahrn-Hansen, B; Madsen, H | 1 |
Bain, AM; Bedimo, R; Busti, AJ; Eaton, SA; Hall, RG; Nguyen, ST; Payne, KD; Rahman, AP; Vu, SL | 1 |
Gale, A; Halverson, J; Lazarus, C | 1 |
Bauer, LA; Blouin, RA; Griffen, WO; Miller, DD; Record, KE | 1 |
Gilliland, SS; Guay, DR; Rodvold, KA; Rotschafer, JC; Vance-Bryan, K | 1 |
Bearden, DT; Rodvold, KA | 1 |
10 review(s) available for vancomycin and Obesity
Article | Year |
---|---|
Open-source maximum a posteriori-bayesian dosing AdDS to current therapeutic drug monitoring: Adapting to the era of individualized therapy.
Topics: Adult; Bayes Theorem; Drug Monitoring; Humans; Obesity; Precision Medicine; Vancomycin | 2021 |
Review and evaluation of vancomycin dosing guidelines for obese individuals.
Topics: Humans; Obesity; Practice Guidelines as Topic; Vancomycin | 2022 |
Towards precision medicine: Therapeutic drug monitoring-guided dosing of vancomycin and β-lactam antibiotics to maximize effectiveness and minimize toxicity.
Topics: Aged; Anti-Bacterial Agents; Area Under Curve; beta-Lactams; Critical Illness; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Bacterial; Humans; Obesity; Precision Medicine; Vancomycin | 2020 |
Obesity-associated changes in drug pharmacokinetics.
Topics: Anti-Bacterial Agents; Body Weight; Humans; Obesity; Pharmaceutical Preparations; Vancomycin | 2020 |
Vancomycin Dosing in Obese Patients: Special Considerations and Novel Dosing Strategies.
Topics: Anti-Bacterial Agents; Bacterial Infections; Humans; Obesity; Vancomycin | 2018 |
Dosing Medications in Obese Patients.
Topics: Aminoglycosides; Dose-Response Relationship, Drug; Enoxaparin; Heparin; Humans; Inpatients; Obesity; Vancomycin | 2015 |
Pharmacotherapy in the critically ill obese patient.
Topics: Aminoglycosides; Antithrombins; Arginine; Body Mass Index; Carbapenems; Cephalosporins; Drug Dosage Calculations; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Hypnotics and Sedatives; Lipopeptides; Obesity; Oxazolidinones; Penicillins; Pipecolic Acids; Protein C; Quinolones; Recombinant Proteins; Safety; Sulfonamides; Vancomycin | 2010 |
Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years.
Topics: Anti-Bacterial Agents; Humans; Obesity; Serum; Vancomycin | 2012 |
[Antibiotics and overweight].
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Body Weight; Cephalosporins; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Humans; Obesity; Penicillins; Quinolones; Vancomycin | 2005 |
Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics.
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Humans; Obesity; Vancomycin | 2000 |
6 trial(s) available for vancomycin and Obesity
Article | Year |
---|---|
Oral vancomycin treatment does not alter markers of postprandial inflammation in lean and obese subjects.
Topics: Adult; Anti-Bacterial Agents; Dietary Fats; Gastrointestinal Microbiome; Humans; Inflammation; Lipopolysaccharides; Male; Metabolic Syndrome; Middle Aged; Monocytes; Obesity; Postprandial Period; Vancomycin | 2019 |
The effects of amoxicillin and vancomycin on parameters reflecting cholesterol metabolism.
Topics: Administration, Oral; Amoxicillin; Anti-Bacterial Agents; Bile Acids and Salts; Cholesterol; Double-Blind Method; Humans; Male; Middle Aged; Obesity; Prediabetic State; Vancomycin | 2017 |
The AAHKS Clinical Research Award: Intraosseous Regional Prophylaxis Provides Higher Tissue Concentrations in High BMI Patients in Total Knee Arthroplasty: A Randomized Trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Arthroplasty, Replacement, Knee; Awards and Prizes; Body Mass Index; Body Weight; Cefazolin; Female; History, 21st Century; Humans; Male; Middle Aged; Obesity; Obesity, Morbid; Orthopedics; Osteoarthritis, Knee; Prospective Studies; Prosthesis-Related Infections; Subcutaneous Fat; Vancomycin | 2018 |
Short-Term Microbiota Manipulation and Forearm Substrate Metabolism in Obese Men: A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Double-Blind Method; Fasting; Fatty Acids, Nonesterified; Forearm; Gastrointestinal Microbiome; Glucose Intolerance; Humans; Insulin Resistance; Male; Middle Aged; Muscle, Skeletal; Obesity; Placebos; Postprandial Period; Vancomycin | 2018 |
Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity.
Topics: Administration, Oral; Adult; Aged; Animals; Anti-Bacterial Agents; Bile Acids and Salts; Feces; Glucose; Humans; Insulin Resistance; Intestines; Male; Metabolic Syndrome; Mice; Microbiota; Middle Aged; Obesity; Single-Blind Method; Vancomycin | 2014 |
Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled Trial.
Topics: Adipocytes; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Biomarkers; Butyric Acid; Cell Shape; Double-Blind Method; Energy Metabolism; Feces; Gastrointestinal Microbiome; Gene Expression Regulation; Humans; Inflammation; Insulin; Male; Middle Aged; Obesity; Organ Specificity; Permeability; Placebos; Substrate Specificity; Vancomycin | 2016 |
43 other study(ies) available for vancomycin and Obesity
Article | Year |
---|---|
Phenylthiazoles with nitrogenous side chain: An approach to overcome molecular obesity.
Topics: Amines; Animals; Anti-Bacterial Agents; Cell Line; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Humans; Macrophages; Male; Methicillin-Resistant Staphylococcus aureus; Mice; Microbial Sensitivity Tests; Molecular Structure; Obesity; Rats; Rats, Sprague-Dawley; Staphylococcal Infections; Structure-Activity Relationship; Thiazoles | 2019 |
Body Mass Index of Elderly Patients with Normal Renal Function as a Determining Factor for Initial Vancomycin Regimen Designing.
Topics: Aged; Anti-Bacterial Agents; Area Under Curve; Body Mass Index; Humans; Kidney; Obesity; Retrospective Studies; Thinness; Vancomycin | 2022 |
Gut Microbiota Regulate Pancreatic Growth, Exocrine Function, and Gut Hormones.
Topics: Amylases; Animals; Diet, High-Fat; Gastrointestinal Microbiome; Glucagon-Like Peptide 1; Humans; Mice; Mice, Inbred C57BL; Obesity; Pancreas; Pancreatic Elastase; Vancomycin | 2022 |
Vancomycin dosing in patients with obesity.
Topics: Anti-Bacterial Agents; Drug Monitoring; Humans; Obesity; Vancomycin | 2022 |
Vancomycin volume of distribution estimation in adults with class III obesity.
Topics: Adult; Aged; Anti-Bacterial Agents; Body Mass Index; Female; Humans; Male; Middle Aged; Obesity; Retrospective Studies; Tissue Distribution; Vancomycin | 2019 |
Evaluation of a modified vancomycin nomogram for obese adults.
Topics: Anti-Bacterial Agents; Body Weight; Creatinine; Female; Humans; Male; Middle Aged; Nomograms; Obesity; Retrospective Studies; Vancomycin | 2020 |
Necrotising fasciitis.
Topics: Abdomen; Adult; Anti-Bacterial Agents; Clindamycin; Coinfection; Debridement; Diabetes Mellitus, Type 2; Fasciitis, Necrotizing; Female; Fluid Therapy; Humans; Meropenem; Methicillin-Resistant Staphylococcus aureus; Obesity; Renal Insufficiency, Chronic; Resuscitation; Staphylococcal Infections; Streptococcal Infections; Streptococcus pyogenes; Vancomycin | 2020 |
The effect of body mass index and creatinine clearance on serum trough concentration of vancomycin in adult patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Body Mass Index; China; Creatinine; Drug Monitoring; Female; Humans; Male; Middle Aged; Multivariate Analysis; Obesity; Retrospective Studies; Vancomycin | 2020 |
Do Vancomycin Pharmacokinetics Differ Between Obese and Non-obese Patients? Comparison of a General-Purpose and Four Obesity-Specific Pharmacokinetic Models.
Topics: Anti-Bacterial Agents; Body Mass Index; Cohort Studies; Humans; Obesity; Vancomycin | 2021 |
A simulation of loading doses for vancomycin continuous infusion regimens in intensive care.
Topics: Aged; Body Weight; Computer Simulation; Critical Care; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged; Obesity; Retrospective Studies; Vancomycin | 2017 |
Allometric versus consensus guideline dosing in achieving target vancomycin trough concentrations.
Topics: Adult; Aged; Anti-Bacterial Agents; Body Size; Body Weight; Consensus; Dose-Response Relationship, Drug; Female; Hospitalization; Humans; Infusions, Intravenous; Male; Middle Aged; Obesity; Practice Guidelines as Topic; Retrospective Studies; Vancomycin | 2017 |
Gut microbiota modulate neurobehavior through changes in brain insulin sensitivity and metabolism.
Topics: Animals; Anti-Bacterial Agents; Anxiety; Brain; Diet, High-Fat; Gastrointestinal Microbiome; Inflammation; Insulin; Insulin Resistance; Male; Metronidazole; Mice; Mice, Inbred C57BL; Microbiota; Obesity; RNA, Ribosomal, 16S; Vancomycin | 2018 |
Antibiotic-induced microbiome depletion alters metabolic homeostasis by affecting gut signaling and colonic metabolism.
Topics: Amphotericin B; Ampicillin; Animals; Anti-Bacterial Agents; Bile Acids and Salts; Blood Glucose; Body Composition; Body Weight; Cecum; Colon; Fatty Acids, Volatile; Gastrointestinal Microbiome; Gene Expression Regulation; Glucose; Homeostasis; Insulin; Insulin Resistance; Male; Metronidazole; Mice; Mice, Inbred C57BL; Neomycin; Obesity; RNA, Ribosomal, 16S; Vancomycin | 2018 |
Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations.
Topics: Aged; Anti-Bacterial Agents; Burns; Child; Critical Illness; Drug Monitoring; Hematologic Diseases; Humans; Infant, Newborn; Models, Biological; Neurosurgical Procedures; Obesity; Renal Insufficiency; Vancomycin | 2018 |
Dosing vancomycin in the super obese: less is more.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Area Under Curve; Body Weight; Creatinine; Drug Dosage Calculations; Drug Monitoring; Female; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Nomograms; Obesity; Staphylococcal Infections; Vancomycin; Young Adult | 2018 |
Vancomycin pharmacokinetics in critically ill obese patients: can the clinician sit back and relax?
Topics: Anti-Bacterial Agents; Critical Illness; Humans; Obesity; Vancomycin | 2019 |
Colonic M1 macrophage is associated with the prolongation of gastrointestinal motility and obesity in mice treated with vancomycin.
Topics: Animals; B7-1 Antigen; Biomarkers; Colon; Cytokines; Disease Models, Animal; Female; Gastrointestinal Motility; Immunohistochemistry; Macrophages; Mice; Obesity; Tetraspanin 30; Vancomycin | 2019 |
Impact of total body weight on rate of acute kidney injury in patients treated with piperacillin-tazobactam and vancomycin.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Body Weight; Drug Therapy, Combination; Female; Humans; Kentucky; Male; Middle Aged; Obesity; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Risk Factors; Vancomycin; Young Adult | 2019 |
Targeting the microbiota to address diet-induced obesity: a time dependent challenge.
Topics: Animals; Biodiversity; Colony Count, Microbial; Diet; Gastrointestinal Tract; Male; Mice; Mice, Inbred C57BL; Microbiota; Obesity; Phylogeny; Principal Component Analysis; Time Factors; Vancomycin; Weight Gain | 2013 |
Vancomycin trough concentrations in overweight or obese pediatric patients.
Topics: Adolescent; Algorithms; Anti-Bacterial Agents; Body Weight; Case-Control Studies; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hospitals, Pediatric; Humans; Male; Obesity; Overweight; Retrospective Studies; Vancomycin | 2013 |
[Endogenous endophthalmitis as a complication in erysipelas].
Topics: Antifungal Agents; Bacteremia; Ceftazidime; Diabetes Mellitus, Type 2; Disease Susceptibility; Drug Therapy, Combination; Endophthalmitis; Erysipelas; Eye Infections, Bacterial; Humans; Imipenem; Intertrigo; Leg; Levofloxacin; Male; Middle Aged; Obesity; Streptococcus agalactiae; Uveitis, Anterior; Vancomycin | 2013 |
Alteration of gut microbiota by vancomycin and bacitracin improves insulin resistance via glucagon-like peptide 1 in diet-induced obesity.
Topics: Animals; Anti-Bacterial Agents; Bacitracin; Bacteroidetes; Blood Glucose; Blotting, Western; Cell Line, Tumor; Diet, High-Fat; Gastrointestinal Tract; Glucagon-Like Peptide 1; Gram-Positive Bacteria; Humans; Insulin; Insulin Resistance; Metabolomics; Mice, Inbred C57BL; Microbiota; Obesity; RNA, Ribosomal, 16S; Sequence Analysis, DNA; Vancomycin | 2015 |
The association of elevated trough serum vancomycin concentrations with obesity.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Body Mass Index; Female; Humans; Male; Middle Aged; Obesity; Retrospective Studies; Vancomycin | 2015 |
Performance of a divided-load intravenous vancomycin dosing strategy for obese patients.
Topics: Administration, Intravenous; Adult; Aged; Anti-Bacterial Agents; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Obesity; Prospective Studies; Vancomycin | 2015 |
Individualized vancomycin dosing in obese patients: a two-sample measurement approach improves target attainment.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Drug Monitoring; Female; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Obesity; Precision Medicine; Staphylococcal Infections; Vancomycin | 2015 |
Bayesian Estimation of Vancomycin Pharmacokinetics in Obese Children: Matched Case-Control Study.
Topics: Adolescent; Anti-Bacterial Agents; Bayes Theorem; Body Mass Index; Case-Control Studies; Child; Child, Preschool; Female; Humans; Ideal Body Weight; Infant; Male; Models, Biological; Obesity; Overweight; Regression Analysis; Retrospective Studies; Vancomycin; Young Adult | 2015 |
Vancomycin-Associated Nephrotoxicity: The Obesity Factor.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Female; Humans; Incidence; Male; Middle Aged; Obesity; Retrospective Studies; Vancomycin | 2015 |
Vancomycin Dosing Considerations in a Real-World Cohort of Obese and Extremely Obese Patients.
Topics: Aged; Anti-Bacterial Agents; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Logistic Models; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Obesity; Obesity, Morbid; Pneumonia, Staphylococcal; Retrospective Studies; Vancomycin | 2015 |
Daily vancomycin dose requirements as a continuous infusion in obese versus non-obese SICU patients.
Topics: Adult; Aged; Anti-Bacterial Agents; APACHE; Attention; Body Mass Index; Cohort Studies; Critical Illness; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Intensive Care Units; Male; Middle Aged; Obesity; Retrospective Studies; Vancomycin | 2016 |
Antibiotic dosing in obesity: a BIG challenge.
Topics: Anti-Bacterial Agents; Critical Illness; Humans; Infections; Obesity; Vancomycin | 2016 |
Peak Measurement for Vancomycin AUC Estimation in Obese Adults Improves Precision and Lowers Bias.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Area Under Curve; Bayes Theorem; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Obesity; Vancomycin | 2017 |
Vancomycin treatment of infective endocarditis is linked with recently acquired obesity.
Topics: Age Factors; Aged; Anti-Bacterial Agents; Body Mass Index; Drug Therapy, Combination; Endocarditis; Female; Gentamicins; Humans; Life Style; Male; Middle Aged; Obesity; Retrospective Studies; Sex Factors; Surveys and Questionnaires; Vancomycin; Weight Gain | 2010 |
Vancomycin dosing in obese pediatric patients.
Topics: Anti-Bacterial Agents; Body Weight; Case-Control Studies; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Male; Obesity; Overweight; Retrospective Studies; Vancomycin | 2011 |
Determining vancomycin clearance in an overweight and obese population.
Topics: Aged; Body Weight; Female; Hospitals, Veterans; Humans; Male; Metabolic Clearance Rate; Middle Aged; Obesity; Overweight; Retrospective Studies; Vancomycin; Veterans | 2011 |
Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bias; Computer Simulation; Dose-Response Relationship, Drug; Drug Dosage Calculations; Female; Humans; Kidney Diseases; Male; Middle Aged; Models, Biological; Obesity; Practice Guidelines as Topic; Prospective Studies; Software; Time Factors; Vancomycin; Young Adult | 2011 |
Evaluation of the accuracy of a pharmacokinetic dosing program in predicting serum vancomycin concentrations in critically ill patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Critical Illness; Drug Monitoring; Female; Humans; Infusions, Intravenous; Intensive Care Units; Male; Middle Aged; Models, Biological; Multiple Organ Failure; Obesity; Prospective Studies; Renal Insufficiency; Severity of Illness Index; Software; Vancomycin | 2011 |
Vancomycin dosage in overweight and obese children.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hospitals, Pediatric; Humans; Infusions, Intravenous; Logistic Models; Male; Multivariate Analysis; Obesity; Overweight; Retrospective Studies; Vancomycin | 2011 |
Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacteriocins; Blood Glucose; Diet, High-Fat; Drug Delivery Systems; Gene Expression; Inflammation; Intestinal Mucosa; Intestines; Lactobacillus; Male; Metagenome; Mice; Mice, Inbred C57BL; Obesity; Probiotics; Triglycerides; Tumor Necrosis Factor-alpha; Vancomycin; Weight Gain | 2013 |
Performance of a vancomycin dosage regimen developed for obese patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Creatinine; Dose-Response Relationship, Drug; Female; Humans; Kidney Diseases; Male; Middle Aged; Obesity; Retrospective Studies; Vancomycin | 2012 |
Multicenter evaluation of vancomycin dosing: emphasis on obesity.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Body Mass Index; Comorbidity; Creatinine; Female; Humans; Male; Middle Aged; Obesity; Pilot Projects; Vancomycin | 2008 |
D-lactic acidosis and other complications of intestinal bypass surgery.
Topics: Acidosis; Ataxia; Bicarbonates; Dysarthria; Female; Humans; Ileum; Jejunum; Lactates; Middle Aged; Obesity; Postoperative Complications; Syndrome; Vancomycin | 1984 |
Vancomycin pharmacokinetics in normal and morbidly obese subjects.
Topics: Adult; Female; Humans; Kinetics; Male; Obesity; Vancomycin | 1982 |
Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bayes Theorem; Body Weight; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Obesity; Retrospective Studies; Vancomycin | 1993 |